Vaxcell’s NK Cell Therapy Combo Shows Phase IIa Promise In HCC
But Analyst Sees Need For Further Data
Korean bioventure’s interim Phase IIa data for locoregional high-dose, autologous natural killer cell therapy in hepatocellular carcinoma in combination with HAIC look "promising," but further safety data awaited.
You may also be interested in...
At a recent forum in Seoul, an executive of Hanmi Pharmaceuticals, whose novel neutropenia drug has just received a US green light, shares why it is crucial to create "blue oceans" through global innovative drug development and how the Korean firm plans to challenge these markets.
Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.
The number of approvals under a South Korean fast-track scheme launched around two years ago has increased, led more recently by COVID-19 vaccines and treatments, as well as anticancer drugs. Meanwhile, a new breakthrough therapy program similar to that in the US has been introduced to prioritize and speed up regulatory reviews of innovative medicines.